Jubilant Ingrevia Ltd. Share Price

Jubilant Ingrevia Ltd – Bullish Reversal Near Support

The stock is showing early signs of recovery after a prolonged correction, with price bouncing from the ₹637–611 support zone and short-term momentum improving. 🔎 Technical View: • Rebound from key support zone • Bullish candle formation near ₹637 • Momentum starting to improve • RSI recovering from lower levels • Price attempting to reclaim ₹663 resistance 🔑 Key Levels: • Support: ₹637 – ₹611 • Major Support: ₹584 • Resistance: ₹664 – ₹684 • Major Resistance: ₹717 – ₹743 🚀 Targets: • ₹684 • ₹717 • ₹743+ 📉 Risk: Break below ₹611 may weaken the setup. 📈 View: Sustained move above ₹664 may support further recovery toward higher resistance levels. ⚠️ For educational purposes only. Not a buy/sell recommendation. — AALGO BREATHS 📊

See More

JUBLINGREA — Jubilant Ingrevia Ltd. SWOT Analysis

Strengths Diversified specialty-chemicals portfolio with 130+ products across 35+ chemistry platforms. Serves 1,600+ customers in 63 countries, giving it a broad global customer base. Strong presence across pharma, agrochemicals, nutrition, consumer and industrial applications. Integrated chemistry capabilities and established manufacturing infrastructure. CDMO business provides potential for higher-value, customer-specific solutions. FY26 consolidated revenue increased to ₹4,388 Cr, while EBITDA rose to ₹607 Cr and PAT to ₹278 Cr. Weaknesses Earnings remain exposed to specialty-chemical pricing and realization cycles. Several products can experience margin pressure when raw-material costs rise faster than selling prices. Manufacturing shutdowns or operational issues can affect volumes, as seen previously at the Nira plant. Chemical manufacturing is relatively capital- and energy-intensive. International operations expose the company to currency and global-demand fluctuations. Opportunities Expansion of CDMO/customised specialty chemicals for global pharmaceutical and agrochemical customers. Growing demand for India-based chemical supply chains and import substitution. Higher-value products in nutrition, life sciences and advanced specialty chemistry. Increasing global interest in sustainable chemistry and bio-based products. Expansion into semiconductor and other specialised industrial applications. Threats Competition from Chinese and other Asian chemical manufacturers. Volatility in raw-material and energy prices. Global chemical-cycle downturns can pressure realizations and capacity utilisation. Environmental, safety and regulatory requirements can increase compliance costs. Customer concentration/product-specific demand cycles and international trade disruptions.

See More

THE QSR STORY IS NO LONGER JUST ABOUT OPENING STORES

For years, the simple QSR growth story was: open more restaurants, serve more customers, grow revenue. But the latest numbers tell a different story. Jubilant FoodWorks offers an interesting case study.

Its Q1 FY27 standalone revenue rose 9.2% YoY to ₹1,849 crore, while Domino’s India contributed roughly 95% of that revenue. The company also expanded to 2,513 stores. But here is the important lesson: Store growth alone does not tell us whether the underlying business is becoming stronger. Domino’s like-for-like sales growth improved to 2.5%, compared with just 0.2% in the previous quarter. Order volumes increased 6.5% YoY. Delivery remains a major growth engine, with delivery revenue growing 12.1%. However, delivery also carries higher costs through delivery operations, discounts and other expenses. So Jubilant is also working on its physical stores, upgrading around 400 Domino’s outlets to improve service, throughput and customer experience. Then comes Popeyes. Revenue almost doubled, like-for-like growth remained above 40% for the third consecutive quarter, and the brand reached 88 stores. This could eventually become another growth engine, although it remains much smaller than Domino’s. The bigger analytical question is therefore: Can Jubilant convert order growth, store expansion and new-brand growth into sustainable same-store growth and stronger margins? That is the kind of question investors should study not simply whether the company opened more stores. Revenue growth can hide weak stores; always examine same-store sales, order volumes, margins, channel economics and brand-level performance together.

See More

🚀 50 Stocks With Strong Q1 FY27 Concall Commentary 📊🔥

🔹 #SGMART — 🚀 118% EBITDA growth outlook; ₹300 Cr EBITDA target for FY27 🔹 #SENORES — 💊 Targeting 30–40% revenue growth and 50–60% PAT growth in FY27 🔹 #SAKAR — 🧬 25% revenue CAGR with 50%+ PAT growth; oncology business ramp-up is a key catalyst 🔹 #SGFIN — 💰 Targeting 43% PAT growth and ₹225 Cr PAT in FY27 🔹 #SHADOWFAX — 🚚 FY27 revenue growth guidance upgraded sharply to 38–40% 🔹 #NEOGEN — 🔋 ~40% revenue growth expected, supported by battery-chemical expansion 🔹 #HFCL — 🌐 FY27 revenue growth guidance doubled to 40% from 20% 🔹 #SAHASRA — ⚡ Targeting 100% revenue growth and ₹275–300 Cr revenue in FY27 🔹 #SANGAMIND — 📈 Management targeting 100% PAT growth in FY27 🔹 #JSFB — 🏦 80%+ PAT growth outlook, with strong loan and deposit growth targets 🔹 #MOTILALOFS — 🏠 Housing finance AUM expected to grow 20%+ annually over the next 2–3 years 🔹 #BORORENEW — ☀️ Targeting 60% revenue & EBITDA growth; 600 TPD capacity expansion planned 🔹 #MBAPL — 🌾 >50% revenue growth expected in FY27, led by the Dhule SSP ramp-up 🔹 #ATLANTAELE — ⚡ Management sees ~40% revenue CAGR over the next 3 years 🔹 #NETWEB — 🖥️ 35–40% revenue growth outlook with healthy margin expectations 🔹 #SYRMA — 🔌 30–35%+ growth opportunity with strong FY27 targets 🔹 #JUBLINGREA — 🧪 32–40% EBITDA growth target; ₹750–800 Cr EBITDA outlook 🔹 #KRISHANA — 🌱 30–35% revenue growth guidance for FY27 🔹 #ARSSBL — 📊 30–35% PAT growth expected in FY27 🔹 #CGCL — 💰 30%+ AUM CAGR targeted through FY28 🔹 #SOBHA — 🏗️ 30%+ pre-sales growth target for FY27

🔹 #BANDHANBNK — 🏦 20%+ growth targeted in the non-EEB loan book 🔹 #LTF — 💰 20%+ book CAGR targeted through FY31 📌 The common theme: strong management confidence, capacity expansion, new businesses!!

See More

JUBILIANT INGREVIA ENTERS INTO ELECTRONICS MANUFACTURING SECTOR

Specialty chemical player

will be acquiring a 40% stake in Zettaone Technologies for an amount of Rs 189.2 crore. Zettaone Technologies is an electronics design and manufacturing platform with integrated capabilities in electronics & semicon industry. This acquisition will allow the company to capitalise on it's proven manufacturing and customer-centric capabilities in CDMO space, while further strengthening it's engagement with customers across the electronics and semiconductor value chain. After the completion of the proposed acquisition, Zettaone Technologies will become an associate company of Jubilant Ingrevia.

See More

JUBILANT INGREVIA SHARES IN FOCUS AFTER ACQUIRING 40% STAKE IN ZETTAONE TECHNOLOGIES

Jubilant Ingrevia shares are likely to remain in focus after the company’s board approved a binding term sheet to acquire a 40% strategic stake in Zettaone Technologies India for approximately ₹189.2 crore. After completion, Zettaone will become an associate company of Jubilant Ingrevia. The acquisition will be completed in two tranches, with the first expected by November 2026 and the second by September 2027. The acquisition comes after a strong June quarter for Jubilant Ingrevia. The company reported a 41% year-on-year rise in consolidated net profit, while revenue from operations increased 25.3%. EBITDA also grew 40% year-on-year, indicating strong operating performance during the quarter. In the previous trading session, Jubilant Ingrevia closed at ₹725.90, down ₹6.40. The stock’s 52-week high stands at ₹794.95, recorded on July 22, 2026, placing it around 8.69% below the peak. The company currently has a market capitalisation of approximately ₹11,562 crore.

See More